| |
MetS
(n=276) |
Control
(n=335) |
p |
| In-hospital clinical outcomes n (%) |
|
|
|
| Acute stent thrombosis, n (%) |
5 (2%) |
9 (3%) |
0.47 |
| Recurrent myocardial infarction, n (%) |
7 (3%) |
9 (3%) |
0.90 |
| Target lesion revascularization, n (%) |
6 (2%) |
9 (3%) |
0.69 |
| Death, n (%) |
11 (4%) |
7 (2%) |
0.17 |
| Major adverse cardiac events, n (%) |
18 (7%) |
17 (5%) |
0.44 |
Death, recurrent myocardial infarction and target lesion revascularization are accepted as major adverse cardiac events |
